Design and synthesis of pinanamine derivatives as anti-influenza A M2 ion channel inhibitors

Antiviral Research

Volumn 96, Issue 2, 2012, Pages 91-99

  Zhao, Xin ^a   Jie, Yanling ^a   Rosenberg, Matthew R ^c   Wan, Junting ^a   Zeng, Shaogao ^a   Cui, Wei ^a   Xiao, Yiping ^a   Li, Zhiyuan ^a   Tu, Zhengchao ^a   Casarotto, Marco G ^c   Hu, Wenhui ^a,b  

^a GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

^b State Key Laboratory of Respiratory Disease   (China)

^c Biology and Environment   (Australia)

Author keywords

Influenza A virus; M2 ion channel; Pinanamine derivatives

Indexed keywords

ADAMANTANE; AMANTADINE; ANTIVIRUS AGENT; BL 1743; GUANAZOLE; IMIDAZOLE DERIVATIVE; PINANAMINE DERIVATIVE; PROTEIN M2; RIMANTADINE; UNCLASSIFIED DRUG;

ARTICLE; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; INFLUENZA VIRUS A; MUTANT; PRIORITY JOURNAL; WILD TYPE;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; HUMANS; INFLUENZA A VIRUS; ION CHANNELS; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; VIRAL MATRIX PROTEINS; VIRAL PLAQUE ASSAY;

INFLUENZA A VIRUS;

EID: 84867026687     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2012.09.001     Document Type: Article

References (48)

1. Abed Y., Goyette N., Boivin G. Generation and characterization of recombinant influenza A (H1N1) viruses harboring amantadine resistance mutations. Antimicrob. Agents Chemother. 2005, 49:556-559.
2. Aldrich P.E., Hermann E.C., Meier W.E., Paulshock M., Prichard W.W., Snyder J.A., Watts J.C. Antiviral agents 2. Structure-activity relations of compounds related to 1-adamantanamine. J. Med. Chem. 1971, 14:535-543.
3. Arstad E., Platzer S., Berthele A., Pilowsky L.S., Luthra S.K., Westerd HJ., Henriksen G. Towards NR2B receptor selective imaging agents for PET-synthesis and evaluation of N-[11C]-(2-methoxy)benzyl (E)-styrene-, 2-naphthyl- and 4-trifluoromethoxyphenylamidine. Bioorg. Med. Chem. 2006, 14:6307-6313.
4. Baz M., Abed Y., Papenburg J., Bouhy X., Hamelin M.E., Boivin G.N. Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis. Engl. J. Med. 2009, 361:2296-2297.
5. Brown A.N., McSharry J.J., Weng Q., Driebe E.M., Engelthaler D.M., Sheff K., Keim P.S., Nguyen J., Drusano G.L. In vitro system for modeling influenza A virus resistance under drug pressure. Antimicrob. Agents Chemother. 2010, 54:3442-3450.
6. Bright R.A., Medina M.J., Xu X., Perez-Oronoz G., Wallis T.R., Davis X.M., Povinelli L., Cox N.J., Klimov A.I. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 2005, 366:1175-1181.
7. Balannik V., Wang J., Ohigashi Y., Jing X., Magavern E., Lamb R.A., DeGrado W.F., Pinto L.H. Design and pharmacological characterization of inhibitors of amantadine-resistant mutants of the M2 ion channel of influenza A virus. Biochemistry 2009, 48:11872-11882.
8. Couzin-Frankel J. What role for antiviral drugs. Science 2009, 324:705.
9. Ciampor F., Bayley P.M., Nermut M.V., Hirst E.M.A., Sugrue R.J., Hay A.J. Evidence that the amantadine-induced, M2-mediated conversion of influenza A virus hemagglutinin to the low pH conformation occurs in an acidic trans Golgi compartment. Virology 1992, 188:14-24.
10. De Clercq E. Antiviral agents active against influenza A viruses. Nat. Rev. Drug Discov. 2006, 5:1015-1025.
11. Davies W.L., Grunert R.R., Haff R.F., Mcgahen J.W., Neumayer E.M., Paulshock M., Hermann E.C., Hoffmann C.E. Antiviral activity of 1-adamantanamine (amantadine). Science 1964, 144:862-863.
12. Duque M.D., Ma C., Torres E., Wang J., Naesens L., Juarez-Jimenez J., Camps P., Javier Luque F., DeGrado W.F., Lamb R.A., Pinto L.H., Vazquez S. Exploring the size limit of templates for inhibitors of the M2 ion channel of influenza A virus. J. Med. Chem. 2011, 54:2646-2657.
13. Grambas S., Hay A.J. Maturation of influenza a virus hemagglutinin-estimates of the pH encountered during transport and its regulation by the M2 protein. Virology 1992, 190:11-18.
14. Hu J., Fu R., Nishimura K., Zhang L., Zhou H.-X., Busath D.D., Vijayvergiya V., Cross T.A. Histidines, heart of the hydrogen ion channel from influenza A virus: toward an understanding of conductance and proton selectivity. Proc. Natl. Acad. Sci. USA 2006, 103:6865-6870.
15. Hu W., Zeng S., Li C., Jie Y., Li Z., Chen L. Identification of hits as matrix-2 protein inhibitors through the focused screening of a small primary amine library. J. Med. Chem. 2010, 53:3831-3834.
16. Hu F., Luo W., Hong M. Mechanisms of proton conduction and gating in Influenza M2 proton channels from solid-state NMR. Science 2010, 330:505-508.
17. Judd A.K., Sanchez A., Bucher D.J., Huffman J.H., Bailey K., Sidwell R.W. In vivo anti-influenza virus activity of a zinc finger peptide. Antimicrob. Agents Chemother. 1997, 41:687-692.
18. Kilbourne E.D. Influenza pandemics of the 20th century. Emerg. Infect. Dis. 2006, 12:9-14.
19. Kolocouris N., Foscolos G.B., Kolocouris A., Marakos P., Pouli N., Fytas G., Ikeda S., Clercq E.D. Synthesis and antiviral activity evaluation of some amino adamantane derivatives. J. Med. Chem. 1994, 37:2896-2902.
20. Kolocouris N., Kolocouris A., Foscolos G.B., Fytas G., Neyts J., Padalko E., Balzarini J., Snoeck R., Andrei G., Clercq E.D. Synthesis and antiviral activity evaluation of some new aminoadamantane derivatives. 2. J. Med. Chem. 1996, 39:3307-3318.
21. Kolocouris A., Tataridis D., Fytas G., Mavromoustakos G., Foscolos G.B., Kolocouris N., Clercq E.D. Synthesis of 2-(2adamantyl)pipeidines and structure anti-influenza virus A activity relationship study using a combination of NMR spectroscopy and molecular modeling. Bioorg. Med. Chem. Lett. 1999, 9:3465-3470.
22. Li D., Saito R., Suzuki Y., Sato I., Zaraket H., Dapat C., Caperig-Dapat I.M., Suzuki H. In vivo and in vitro alterations in influenza A/H3N2 virus M2 and hemagglutinin genes: effect of passage in MDCK-SIAT1 cells and conventional MDCK cells. J. Clin. Microbiol. 2009, 47:466-468.
23. Li S., Chiu G., Pulito V.L., Liu J., Connolly P.J., Middleton S.A. 1-Arylpiperazinyl-4-cyclohexylamine derived isoindole-1,3-diones as potent and selective α-1a/1d adrenergic receptor ligands. Bioorg. Med. Chem. Lett. 2007, 17:1646-1650.
24. Munster V.J., Wallensten A., Baas C., Rimmelzwaan G.F., Schutten M., Olsen B., Osterhaus A.D., Fouchier R.A. Mallards and highly pathogenic avian influenza ancestral viruses, northern Europe. Emerg. Infect. Dis. 2005, 11:1545-1551.
25. Martin K., Heleniust A. Nuclear transport of influenza virus ribonucleoproteins: the viral matrix protein (M1) promotes export and inhibits import. Cell 1991, 67:117-130.
26. Okada A., Miura T., Takeuchi H. Protonation of histidine and histidine-tryptophan interaction in the activation of the M2 ion channel from influenza A virus. Biochemistry 2001, 40:6053-6060.
27. Pinto L.H., Dieckmann G.R., Gandhi C.S., Braman J., Shaughnessy M.A., Lear J.D., Lamb R.A., DeGrado W.F. A functionally defined model for the M2 proton channel of influenza A virus suggests a mechanism for its ion selectivity. Proc. Natl. Acad. Sci. USA 1997, 94:11301-11306.
28. Rosenberg M.R., Casrotto M.G. Coexistence of two adamantine binding sites in the influenza A M2 ion channel. Proc. Natl. Acad. Sci. USA 2010, 107:13866-13871.
29. Sakaguchi T., Tu Q., Pinto L.H., Lamb R.A. The active oligomeric state of the minimalistic influenza virus M2 ion channel is a tetramer. Proc. Natl. Acad. Sci. USA 1997, 94:5000-5005.
30. Stouffer A.L., Acharya R., Salom D., Levine A.S., Costanzo L.D., Soto C.S., Tereshko V., Nanda V., Stayrook S., DeGrado W.F. Structural basis for the function and inhibition of an influenza virus proton channel. Nature 2008, 451:596-599.
31. Schnell J.R., Chou J.J. Structure and mechanism of the M2 proton channel of influenza A virus. Nature 2008, 451:591-595.
32. Saito R., Sakai T., Sato I., Sano Y., Oshitani H., Sato M., Suzuki H. Frequency of amantadine-resistant influenza A viruses during two seasons featuring cocirculation of H1N1 and H3N2. J. Clin. Microbiol. 2003, 41:2164-2165.
33. Stead D., O'Brien P., Sanderson A. A new sparteine surrogate for asymmetric deprotonation of N-Boc pyrrolidine. Org. Lett. 2008, 10:1409-1412.
34. Sidwell R.W., Smee D.F. In vitro and in vivo assay systems for study of influenza virus inhibitors. Antiviral Res. 2000, 48:1-16.
35. Takeuchi H., Okada A., Miura T. Roles of the histidine and tryptophan side chains in the M2 proton channel from influenza A virus. FEBS Lett. 2003, 552:35-38.
36. Vaidyanathan R., Kalthod V.G., Ngo D.P., Manley J.M., Lapekas S.P. Amidations using N,N'-carbonyldiimidazole: remarkable rate enhancement by carbon dioxide. J. Org. Chem. 2004, 69:2565-2568.
37. WHO, 2006. Avian Influenza. Available from: <>. http://www.who.int/csr/disease/avianinfluenza/en/index.html.
38. Wang J., Cady S.D., Balannik V, Pinto L.H., DeGrado W.F., Hong M. Discovery of spiro-piperidine inhibitors and their modulation of the dynamics of the M2 proton channel from influenza a virus. J. Am. Chem. Soc. 2009, 131:8066-8076.
39. Wang J., Ma C., Fiorin G., Carnevale V., Wang T., Hu F., Lamb R.A., Pinto L.H., Hong M., Klein M.L., DeGrado W.F. Molecular dynamics simulation directed rational design of inhibitors targeting drug-resistant mutants of influenza A virus M2. J. Am. Chem. Soc. 2011, 133:12834-12841.
40. Wang J., Ma C., Balannik V., Pinto L.H., Lamb R.A., DeGrado W.F. Exploring the requirements for the hydrophobic scaffold and polar amine in inhibitors of M2 from influenza A virus. ACS Med. Chem. Lett. 2011, 2:307-312.
41. Wang C., Lamb R.A., Pinto L.H. Activation of the M2 ion channel of influenza virus: a role for the transmembrane domain histidine residue. Biophys. J. 1995, 69:1363-1371.
42. 41 participates in the gating mechanism of the M2 proton channel of influenza A virus. J. Am. Chem. Soc. 2008, 130:918-924.
43. 18F-labeled guanidines. J. Med. Chem. 1991, 34:1867-1870.
44. Yeh J.Y., Coumar M.S., Horng J.T., Shiao H.Y., Huo F.M., Lee H.L., Chen I.C., Chang C.W., Tang W.F., Tseng S.N., Chen C.J., Shih S.R., Hsu J.A., Liao C.C., Chao Y.S., Hsieh H.P. Anti-influenza drug discovery: structure-activity relationship and mechanistic insight into novel angelicin derivatives. J. Med. Chem. 2010, 53:1519-1533.
45. Zhirnov O.P. Solubilization of matrix protein M1/M from virions occurs at different pH for orthomyxo- and paramyxoviruses. Virology 1990, 176:274-279.
46. Zoidis G., Fytas C., Papanastasiou I., Foscolos G.B., Fytas G., Padalko E., Clercq E.D., Naesens L., Neyts J., Kolocouris N. Heterocyclic rimantadine analogues with antiviral activity. Bioorg. Med. Chem. 2006, 14:3341-3348.
47. Zoidis G., Kolocouris N., Naesens L., Clercq E.D. Design and synthesis of 1,2-annulated adamantane piperidines with anti-influenza virus activity. Bioorg. Med. Chem. 2009, 17:1534-1541.
48. Zhao X., Li C., Zeng S., Hu W. Discovery of highly potent agents against influenza A virus. Eur. J. Med. Chem. 2011, 46:52-57.